Literature DB >> 33466296

Discovering Genotype Variants in an Infant with VACTERL through Clinical Exome Sequencing: A Support for Personalized Risk Assessment and Disease Prevention.

Gloria Pelizzo1,2, Luigi Chiricosta3, Emanuela Mazzon3, Gian Vincenzo Zuccotti2,4, Maria Antonietta Avanzini5, Stefania Croce5, Mario Lima6, Placido Bramanti3, Valeria Calcaterra4,7.   

Abstract

Congenital anomalies may have an increased risk of noncommunicable diseases (NCDs) We performed a clinical exome analysis in an infant affected by "Vertebral, Anorectal, Cardiac, Tracheoesophageal, Genitourinary, and Limb" (VACTERL) malformation association to identify potential biomarkers that may be helpful for preventing malignancy risk or other chronic processes. Among the variants, six variants that may be linked with VACTERL were identified in the exome analysis. The variants c.501G>C on OLR1 and c.-8C>G on PSMA6 were previously associated with myocardial infarction. The variants c.1936A>G on AKAP10 and c.575A>G on PON1 are linked to defects in cardiac conduction and artery disease, respectively. Alterations in metabolism were also suggested by the variants c.860G>A on EPHX2 and c.214C>A on GHRL. In addition, three variants associated with colon cancer were discovered. Specifically, the reported variants were c.723G>A on CCND1 and c.91T>A on AURKA proto-oncogenes as well as c.827A>C in the tumor suppressor PTPRJ. A further inspection identified 15 rare variants carried by cancer genes. Specifically, these mutations are located on five tumor suppressors (SDHA, RB1CC1, PTCH1, DMBT1, BCR) and eight proto-oncogenes (MERTK, CSF1R, MYB, ROS1, PCM1, FGFR2, MYH11, BRCC3) and have an allele frequency lower than 0.01 in the Genome Aggregation Database (GnomAD). We observed that the cardiac and metabolic phenotypic traits are linked with the genotype of the patient. In addition, the risk of developing neoplasia cannot be excluded a priori. Long-term surgical issues of patients with VATER syndrome could benefit from the clinical exome sequencing of a personalized risk assessment for the appearance of further disease in pubertal timing and adult age.

Entities:  

Keywords:  VACTERL; exome sequencing; healthcare; infant; personalized; prevention; risk

Year:  2021        PMID: 33466296      PMCID: PMC7838983          DOI: 10.3390/pediatric13010006

Source DB:  PubMed          Journal:  Pediatr Rep        ISSN: 2036-749X


  66 in total

1.  Deleted in Malignant Brain Tumors 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer.

Authors:  J Mollenhauer; S Herbertz; B Helmke; G Kollender; I Krebs; J Madsen; U Holmskov; K Sorger; L Schmitt; S Wiemann; H F Otto; H J Gröne; A Poustka
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  Suppression of autophagy by FIP200 deletion impairs DNA damage repair and increases cell death upon treatments with anticancer agents.

Authors:  Heekyong Bae; Jun-Lin Guan
Journal:  Mol Cancer Res       Date:  2011-08-01       Impact factor: 5.852

Review 3.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

4.  Somatic Mutations and Intratumoral Heterogeneity of MYH11 Gene in Gastric and Colorectal Cancers.

Authors:  Yun Sol Jo; Min Sung Kim; Nam Jin Yoo; Sug Hyung Lee
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-09

5.  ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.

Authors:  Al Charest; Erik W Wilker; Margaret E McLaughlin; Keara Lane; Ram Gowda; Shanie Coven; Kevin McMahon; Steven Kovach; Yun Feng; Michael B Yaffe; Tyler Jacks; David Housman
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

Review 6.  VACTERL/VATER Association.

Authors:  Benjamin D Solomon
Journal:  Orphanet J Rare Dis       Date:  2011-08-16       Impact factor: 4.123

7.  DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands.

Authors:  Caroline End; Floris Bikker; Marcus Renner; Gaby Bergmann; Stefan Lyer; Stephanie Blaich; Melanie Hudler; Burkhard Helmke; Nikolaus Gassler; Frank Autschbach; Antoon J M Ligtenberg; Axel Benner; Uffe Holmskov; Peter Schirmacher; Arie V Nieuw Amerongen; Philip Rosenstiel; Christian Sina; Andre Franke; Mathias Hafner; Petra Kioschis; Stefan Schreiber; Annemarie Poustka; Jan Mollenhauer
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

8.  Patched controls the Hedgehog gradient by endocytosis in a dynamin-dependent manner, but this internalization does not play a major role in signal transduction.

Authors:  Carlos Torroja; Nicole Gorfinkiel; Isabel Guerrero
Journal:  Development       Date:  2004-04-21       Impact factor: 6.868

Review 9.  Ghrelin.

Authors:  T D Müller; R Nogueiras; M L Andermann; Z B Andrews; S D Anker; J Argente; R L Batterham; S C Benoit; C Y Bowers; F Broglio; F F Casanueva; D D'Alessio; I Depoortere; A Geliebter; E Ghigo; P A Cole; M Cowley; D E Cummings; A Dagher; S Diano; S L Dickson; C Diéguez; R Granata; H J Grill; K Grove; K M Habegger; K Heppner; M L Heiman; L Holsen; B Holst; A Inui; J O Jansson; H Kirchner; M Korbonits; B Laferrère; C W LeRoux; M Lopez; S Morin; M Nakazato; R Nass; D Perez-Tilve; P T Pfluger; T W Schwartz; R J Seeley; M Sleeman; Y Sun; L Sussel; J Tong; M O Thorner; A J van der Lely; L H T van der Ploeg; J M Zigman; M Kojima; K Kangawa; R G Smith; T Horvath; M H Tschöp
Journal:  Mol Metab       Date:  2015-03-21       Impact factor: 7.422

10.  MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma.

Authors:  Li-Hua Xu; Fei Zhao; Wen-Wen Yang; Chu-Wen Chen; Zhi-Hao Du; Min Fu; Xi-Yuan Ge; Sheng-Lin Li
Journal:  Int J Oncol       Date:  2019-03-18       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.